Chas Pulido

Chas Pulido is an experienced investor and entrepreneur, currently serving as an Investor at Exthymic since 2024 and also acting as the Founder and General Partner at Alix Ventures since 2020, focusing on early-stage Life Science startups. In addition to these roles, Chas Pulido has created initiatives to unite the Life Science ecosystem through BIOS, and holds investor positions in various companies, including Mythic Therapeutics, Strand Therapeutics, ELEGEN, Chemify Limited, Galatea Bio Inc., Zafrens, and Cytosolix, significantly contributing to advancements in human health and therapeutic innovations. Chas Pulido's educational background includes studies at Y Combinator, the University of Notre Dame's Mendoza College of Business, and The Bishop's School.